Clinical Trials Logo

Locally Advanced Solid Tumor clinical trials

View clinical trials related to Locally Advanced Solid Tumor.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06416007 Not yet recruiting - Cancer Clinical Trials

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

NCT ID: NCT06415487 Not yet recruiting - Clinical trials for Metastatic Solid Tumor

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Start date: May 31, 2024
Phase: Phase 1
Study type: Interventional

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).

NCT ID: NCT06349408 Not yet recruiting - Clinical trials for Locally Advanced Solid Tumor

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Start date: May 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. It includes a Phase 1 section to identify Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of IBI3001, and a Phase 2 section to explore and confirm the efficacy, safety and tolerability of IBI3001 at its RP2D.

NCT ID: NCT05218148 Not yet recruiting - Immunotherapy Clinical Trials

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

The SOX regimen has became the standard perioperative chemotherapy for locally advanced gastric cancer; The immune checkpoint inhibitors have become a standard treatment for advanced or metastatic gastric cancer;For HER2-positive locally advanced gastric cancer, some phase II studies have shown that chemotherapy combined with trastuzumab can further improve the pathological remission rate;This prospective phase II clinical trial was designed, using SOX combined with sintilimab and trastuzumab to treat HER2 positive locally advanced gastric or gastroesophageal junction adenocarcinoma patients.

NCT ID: NCT05028478 Not yet recruiting - Clinical trials for Hematologic Malignancies

A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Start date: October 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and anti-tumor activity of CN202 in adult subjects with locally advanced or metastatic solid tumor or hematologic malignancies